Phaseline

Targets › EEF2

EEF2 (Elongation factor 2): drug programs, companies and trials

2 programs from 2 companies in 12 trials: 8 Phase 1, 4 Phase 2; Oncology; next expected readout Feb 2028.

Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post-translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively. (UniProt, P13639)

Open in Phaseline: the race on EEF2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Stemline TherapeuticsTagraxofusp
Interleukin-3 receptor subunit alpha binding agent; Elongation factor 2 inhibitor
IL3RA, EEF2Phase 2Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Myelofibrosis …Feb 2028
Alexander B Olawaiye, MDDenileukin Diftitox (E7777)
Elongation factor 2 inhibitor; Interleukin-2 receptor binding agent
EEF2, IL2RA, IL2RG, IL2RBPhase 1Epithelial Ovarian CancerMay 2030

Conditions

Acute Myeloid Leukemia (4) Epithelial Ovarian Cancer (1) Blastic Plasmacytoid Dendritic Cell Neoplasm (1) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (1) Myelofibrosis (1) Chronic Myelomonocytic Leukemia (1) Refractory Acute Myeloid Leukemia (1) Hematologic Malignancy (1) Acute Myeloid Leukaemia (AML) (1)

Modalities

mixed (1), small molecule (1)

Companies

Alexander B Olawaiye, MD (1) Stemline Therapeutics (1)

Related targets

IL2RA (1) IL2RG (1) IL2RB (1) IL3RA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.